Tirzepatide: Understanding Two Incretin Receptors and One Clinical Trial

What “dual agonist” actually means

Tirzepatide is a peptide that activates two receptor types: the glucose-dependent insulinotropic polypeptide receptor, usually shortened to GIP receptor, and the glucagon-like peptide-1 receptor, or GLP-1 receptor. An agonist binds to a receptor and activates its signalling. “Dual” therefore describes two molecular targets—not two separate medicines mixed together, and not activity at GLP-2.

GIP and GLP-1 are incretin hormones involved in coordinating the response to food. Their actions include supporting glucose-dependent insulin secretion: the effect depends on the surrounding glucose conditions rather than functioning as an unconditional insulin switch. Tirzepatide is the active substance in Mounjaro; the EMA medicine overview provides regulatory context for that medicinal product, not validation of every material labelled tirzepatide.

From receptor signalling to body weight

Receptors are proteins through which cells detect signals. Activating them can change cellular activity, but a receptor description is not itself a measurement of what happens to a person's weight.

Tirzepatide's pharmacology involves glucose regulation and appetite-related effects. GLP-1 receptor activity also affects gastric emptying. These processes interact over time; they should not be presented as independent benefits that can simply be added together. Nor does activation of a second receptor mathematically predict twice the effect of a single-receptor agonist.

Semaglutide activates the GLP-1 receptor, whereas tirzepatide activates both GIP and GLP-1 receptors. That distinction creates a useful scientific question: do the different molecules produce different outcomes when compared under the same trial conditions? It does not answer the question by itself.

A comparison made within one trial

SURMOUNT-5 directly compared tirzepatide with semaglutide in 751 adults with obesity who did not have type 2 diabetes. It was a randomized, open-label phase 3b trial lasting 72 weeks. Randomization assigned participants to treatment groups; open-label means participants and investigators knew which treatment was being used.

The trial compared subcutaneous treatment at maximum tolerated doses of tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg. These amounts describe the study interventions, not administration guidance. Estimated mean body-weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide, a difference of 6.5 percentage points. Tirzepatide also produced a greater reduction in waist circumference. These findings come from the primary SURMOUNT-5 publication.

The important feature is the shared comparison. Both groups were studied within the same research framework, rather than selected from unrelated trials with different populations, durations and statistical approaches.

What those percentages cannot tell us

The results are group estimates, not a prediction that every participant will lose the reported percentage. Individual responses and treatment tolerability vary. Gastrointestinal adverse events were common in both groups, and the efficacy result should not be read separately from treatment burden and discontinuation.

The trial also does not isolate how much of the difference was caused specifically by GIP receptor activation. It compared two complete molecules and their treatment regimens, not otherwise identical molecules differing only at one receptor.

Finally, a weight endpoint is not interchangeable with a cardiovascular, liver or other clinical endpoint. SURMOUNT-5 supports a defined comparison of weight and waist outcomes in adults with obesity without type 2 diabetes. It does not establish superiority for every outcome, population or formulation.

Keeping the molecule and the product distinct

A compound name identifies the intended active substance. It does not establish the identity, content, formulation or delivery performance of a particular research product. Clinical evidence belongs to the interventions actually investigated. Understanding that boundary makes the dual-receptor mechanism more useful—not less—because it separates a plausible biological explanation from what a trial has demonstrated.